About
Wiesje van der Flier (1975) is full professor and scientific director of Alzheimer Center Amsterdam at Amsterdam UMC, the Netherlands, where she works since 2004. She studied neuropsychology at the University of Utrecht. In addition, she is clinical epidemiologist. She leads the Amsterdam Dementia Cohort, an ongoing memory-clinic based cohort including over 7000 patients with deep phenotyping (MRI, EEG, CSF biomarkers, and PET) and linked biobank (blood, DNA, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at Alzheimer center Amsterdam. Van der Flier has been (co)promotor of >20 theses and is currently supervising ~10 PhD projects. Van der Fliers main research areas are looking for the origin of AD, diagnosis&prognosis, and intervention&prevention. Van der Flier leads ABOARD (A Personalized Medicine Approach for Alzheimer’s Disease), a Dutch public-private partnership of than 30 partners. Together with colleague Philip Scheltens, she has written a book, het Alzheimermysterie, which was published by the Arbeiderspers.
Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). All funding is paid to her institution. WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. All funding is paid to her institution.
WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. All funding is paid to her institution.
WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. All funding is paid to her institution.
WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution.
WF is member of the steering committee of PAVE, and Think Brain Health.
WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain.